The kit shall be used in conjunction with applicable instruments for in vitro qualitative detection of the COVID-19 in human respiratory traction secretion.
COVID-19, a RNA virus, belongs to the coronavirus family as previous SARS-CoV. However, genome sequencing shows there are difference from the previously known virus, COVID-19 is identified as a new virus. The pneumonia caused by COVID-19 is refereed as Novel coronavirus pneumonia (NCP), COVID-19 may cause outbreak and epidemics. Humans infected with COVID-19 manifest signs including respiratory symptoms, fever, cough, shortness of breath and dyspnea. As there is no specific method of treatment, current clinical data confirm the the death rate is about 3%. The kit is designed to assist in the diagnosis of suspected COVID-19 infected person based on medical diagnosis or close contacts.
Test Application: Suspected COVID-19 infected patients or close contacts through medical diagnosis.
The kit follows the antibody sandwich method. Specifically, clinical samples are combined with fluorecently-labeled antibodies (the labeled microspheres in the kit are time-resolved microspheres); then, incubated clinical samples are captured by the coating antibodies at detection line (T line) on the membrane to form an antibody-antigen-antibody complex; the emission spectrum of the fluorescent microspheres is measured at 610nm; the fluorescence intensity increases with the elevated concetration of COVID-19 antigens in the samples; then the amount of COVID-19 antigens in the samples can be calculated according to the standard curve.
- Probe mit oropharyngealer Tupfer wird in Behälter mit Lösung gegeben
- gegeben falls benötigen Sie eine Zentrifuge, sollte die Probe dickflüssig sein oder eine Suspension erzeugen
- 60µL der Testprobenflüssigkeit zum Teststreifen hinzufügen
- Teststreifen für 15 Minuten bei Zimmertemperatur ruhen lassen
- visuelle Inspektion mittel UV-Licht zeigt das Endresultat